Publications by authors named "M D Ayli"
Objective: In this study, we aimed to obtain real-life data on the use of antimyeloma agents, which significantly increase overall survival (OS) in multiple myeloma (MM) patients, in primary plasma cell leukemia (pPCL) patients with poor prognosis.
Materials And Methods: Data from 53 patients who were diagnosed with pPCL between 2011 and 2020 and who used at least one proteasome inhibitor (PI) and/or immunomodulatory (IMID) agent were analyzed retrospectively. Depending on the year of the pPCL diagnosis, 20% leukocytes or ≥2x10/L plasma cells in the peripheral blood was used as a diagnostic criterion.
Article Synopsis
- * About 9.8% of the patients died during hospitalization, with older individuals and those with preexisting kidney issues showing higher mortality rates due to severe injuries and complications.
- * Key factors influencing mortality included age, injury severity, shock, and certain elevated lab values, highlighting the need for better disaster preparedness and health care improvements for future events.
Article Synopsis
- Millions are affected by natural disasters annually, leading to serious medical issues like crush syndrome, which often results in acute kidney injury tied to high mortality rates.
- This study analyzed data from 1024 patients with crush syndrome after the February 2023 earthquakes in Kahramanmaras, focusing on their treatment and outcomes in Turkish hospitals.
- The findings revealed high rates of acute kidney injury and hemodialysis treatment, with a 9.8% in-hospital mortality rate, highlighting the urgent need for improved emergency response training and protocols for managing kidney health in disaster scenarios.
Comparison of Cyclophosphamide-Based Graft Versus Host Disease Prophylaxis after "Allogeneic Stem Cell Transplantation from 9/10 HLA Matched Unrelated Donor'' with Standard Graft Versus Host Disease Prophylaxis after "10/10 HLA Matched Relative Donor'' Transplant.
Int J Hematol Oncol Stem Cell Res
July 2024
Graft Versus Host Disease (GvHD), which can be observed at a rate of 30-80% after allogeneic stem cell transplantation (ASCT) is an important complication that adversely affects the survival and quality of the life of patientsPosttransplant cyclophosphamide (PTCy) effectively prevents GvHD after HLA-haploidentical ASCT. In our study, the use of PTCy in 1-antigen HLA-mismatched unrelated donor (9/10MMUD) ASCT was compared with standard GvHD prophylaxis in HLA-identical related donor (MRD) ASCT. We conducted a retrospective study of the comparison of 42 patients with 9/10 MMUD ASCT receiving PTCy+Methotrexate (MTX)+Calcineurin Inhibitor (CNI) and 37 patients with HLA-identical MRD who received MTX+CNI in 3 bone marrow transplantation centers.
View Article and Find Full Text PDFIntroduction: Effective mobilization of Stem Cells(SCs) to peripheral blood (PB) is crucial for obtaining sufficient CD34 cell numbers via apheresis. The ratio of pre-apheresis PB CD34 cells is the best parameter for predicting the product CD34 cell count. However, quantitating CD34 PB cells requires flow cytometry, which usually takes two or more hours to obtain the results.
View Article and Find Full Text PDF